In contrast, ESRP1 drove invasiveness in ER+ breast cancers independent of EMT, and thus, high ESRP1 expression but not ESRP2 was significantly associated with reduced overall survival in breast cancer patients as well as with poor prognosis in ER+ breast cancers, suggesting that the malignant phenotype of human breast cancer is associated with ESRP1 overexpression (42, 43). The gene discussed is ESRP1; the disease is breast carcinoma.